Nucelion and VeGen Bio partner to manufacture CAR-T therapy in India
By United One News · AI-generated summary of 3 outlets' reporting
Published · Updated
AI-generated summary of the coverage listed below:
Nucelion Therapeutics and VeGen Bio partnered to manufacture a CAR-T cell therapy for multiple myeloma in India.
- Nucelion will serve as the technology transfer, clinical, and commercial stage manufacturing partner for VeGen Bio.
- The collaboration focuses on the lead candidate VL-2511 to improve production economics and expand patient access.
- The partnership aims to bring the dual-target CAR-T cell therapy into Indian clinical trials and commercialization by 2028.
Covered by 3 outlets across the spectrum: 67% left, 33% center, 0% right.
How each side framed it
Left-leaning: Left-leaning sources highlighted the involvement of the Bharat Biotech arm Nucelion, the focus on multiple myeloma, and the upcoming clinical trials. (AI-generated summary of how this side framed it)
New CAR-T therapy for multiple myeloma to enter India trials soon
Center: The center-focused source emphasized the collaboration's goals to improve production economics and expand patient access in India. (AI-generated summary of how this side framed it)
Nucelion Therapeutics, VeGen Bio partner to manufacture CAR-T cell therapy in India
Timeline
First to report: The Hindu BusinessLine (); 3 articles from 3 outlets so far.
Who is covering this story
- Left-leaning (2): The Federal, The Hindu
- Center (1): The Hindu BusinessLine
Sources
- Nucelion Therapeutics, VeGen Bio partner to manufacture CAR-T cell therapy in India — The Hindu BusinessLine (center) ·
- New CAR-T therapy for multiple myeloma to enter India trials soon — The Federal (left-leaning) ·
- Bharat Biotech arm Nucelion, VeGen Bio to partner for CAR-T therapy — The Hindu (left-leaning) ·